Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Medium materiality6/10

Envoy Advances Acclaim CI PMA with Rolling Submissions and 12-Month Data

Aug 10, 2026, 8:04 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive regulatory momentum (modular PMA submission) and encouraging 12-month efficacy data reduce near-term uncertainty and can attract investor interest, though ultimate approval remains contingent on durable data and regulatory timelines.

AI summary

What happened, with direct paths to the underlying reporting

Envoy Medical reported Q2 2026 results and detailed a modular PMA path for its Acclaim cochlear implant. The first PMA module was submitted, and 12-month Stage 1 CNC data showed a meaningful leap in speech perception (53.2% vs 15.2% baseline). If trajectories continue and the final module lands by mid-2027, FDA approval and commercialization could follow, unlocking substantial upside but with notable execution risk.

First module of Modular PMA submitted to FDA for Acclaim CI.
12-month Stage 1 CNC score 53.2% vs baseline 15.2%.
Final PMA module targeted for Q2 2027; four-module plan.
ATM equity facility terminated; cash on hand $19.679M at 6/30/2026.
Q2 2026 net revenue $51k; net loss $7.272M.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.